Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Diagnosing complications and co-morbidities of fibrotic interstitial lung disease.

Margaritopoulos GA, Kokosi MA, Wells AU.

Expert Rev Respir Med. 2019 Jul;13(7):645-658. doi: 10.1080/17476348.2019.1632196. Epub 2019 Jul 5.

PMID:
31215263
2.

In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia is associated with disease progression and mortality.

Mackintosh JA, Desai SR, Adamali H, Patel K, Chua F, Devaraj A, Kouranos V, Kokosi M, Margaritopoulos G, Renzoni EA, Wells AU, Molyneaux PL, Kumar S, Maher TM, George PM.

Eur Respir J. 2019 May 23;53(5). pii: 1802412. doi: 10.1183/13993003.02412-2018. Print 2019 May. No abstract available.

PMID:
30923184
3.

Predicting outcomes in rheumatoid arthritis related interstitial lung disease.

Jacob J, Hirani N, van Moorsel CHM, Rajagopalan S, Murchison JT, van Es HW, Bartholmai BJ, van Beek FT, Struik MHL, Stewart GA, Kokosi M, Egashira R, Brun AL, Cross G, Barnett J, Devaraj A, Margaritopoulos G, Karwoski R, Renzoni E, Maher TM, Wells AU.

Eur Respir J. 2019 Jan 3;53(1). pii: 1800869. doi: 10.1183/13993003.00869-2018. Print 2019 Jan.

4.

Pirfenidone improves survival in IPF: results from a real-life study.

Margaritopoulos GA, Trachalaki A, Wells AU, Vasarmidi E, Bibaki E, Papastratigakis G, Detorakis S, Tzanakis N, Antoniou KM.

BMC Pulm Med. 2018 Nov 23;18(1):177. doi: 10.1186/s12890-018-0736-z.

5.

Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial.

Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, Pavitt MJ, Alfieri V, Canu S, Bonifazi M, Boccabella C, De Lauretis A, Stock CJW, Saunders P, Montgomery A, Hogben C, Stockford A, Pittet M, Brown J, Chua F, George PM, Molyneaux PL, Margaritopoulos GA, Kokosi M, Kouranos V, Russell AM, Birring SS, Chetta A, Maher TM, Cullinan P, Hopkinson NS, Banya W, Whitty JA, Adamali H, Spencer LG, Farquhar M, Sestini P, Wells AU, Renzoni EA.

Lancet Respir Med. 2018 Oct;6(10):759-770. doi: 10.1016/S2213-2600(18)30289-3. Epub 2018 Aug 28.

6.

Paroxysmal cough and left sacroiliac joint pain in a 50-year-old Caucasian man.

Proklou A, Bolaki M, Vassalou EE, Bibaki E, Vasarmidi E, Margaritopoulos GA, Karantanas AH, Tzanakis N, Antoniou KM.

Breathe (Sheff). 2018 Jun;14(2):e59-e67. doi: 10.1183/20734735.018818.

7.

Investigation of key autophagy-and mitophagy-related proteins and gene expression in BALF cells from patients with IPF and RA-ILD.

Vasarmidi E, Sarantoulaki S, Trachalaki A, Margaritopoulos G, Bibaki E, Spandidos DA, Tzanakis N, Antoniou K.

Mol Med Rep. 2018 Oct;18(4):3891-3897. doi: 10.3892/mmr.2018.9356. Epub 2018 Aug 6.

8.

Personalised medicine in interstitial lung diseases: Number 6 in the Series "Personalised medicine in respiratory diseases" Edited by Renaud Louis and Nicolas Roche.

Kokosi MA, Margaritopoulos GA, Wells AU.

Eur Respir Rev. 2018 Apr 13;27(148). pii: 170117. doi: 10.1183/16000617.0117-2017. Print 2018 Jun 30. Review.

9.

miR-185 and miR-29a are similarly expressed in the bronchoalveolar lavage cells in IPF and lung cancer but common targets DNMT1 and COL1A1 show disease specific patterns.

Bibaki E, Tsitoura E, Vasarmidi E, Margaritopoulos G, Trachalaki A, Koutoulaki C, Georgopoulou T, Spandidos DA, Tzanakis N, Antoniou KM.

Mol Med Rep. 2018 May;17(5):7105-7112. doi: 10.3892/mmr.2018.8778. Epub 2018 Mar 19.

10.

Upregulation of citrullination pathway: From Autoimmune to Idiopathic Lung Fibrosis.

Samara KD, Trachalaki A, Tsitoura E, Koutsopoulos AV, Lagoudaki ED, Lasithiotaki I, Margaritopoulos G, Pantelidis P, Bibaki E, Siafakas NM, Tzanakis N, Wells AU, Antoniou KM.

Respir Res. 2017 Dec 29;18(1):218. doi: 10.1186/s12931-017-0692-9.

11.

Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.

Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium.

Eur Respir J. 2017 Aug 31;50(2). pii: 1700936. doi: 10.1183/13993003.00936-2017. Print 2017 Aug.

12.

Controversies in Fibrosis and Emphysema.

Antoniou KM, Bibaki E, Margaritopoulos GA.

Arch Bronconeumol. 2017 May;53(5):231-232. doi: 10.1016/j.arbres.2017.02.003. Epub 2017 Mar 23. English, Spanish. No abstract available.

13.

Reply: Is a Trial of Vitamin K Antagonists and Bisphosphonates Possible in IPF?

Margaritopoulos GA, Antoniou KM.

Am J Respir Crit Care Med. 2017 Jan 15;195(2):271-272. doi: 10.1164/rccm.201608-1636LE. No abstract available.

PMID:
28084829
14.

Comorbidities in interstitial lung diseases.

Margaritopoulos GA, Antoniou KM, Wells AU.

Eur Respir Rev. 2017 Jan 3;26(143). pii: 160027. doi: 10.1183/16000617.0027-2016. Print 2017 Jan. Review.

15.

Reply: Heparin versus Warfarin in Interstitial Pulmonary Fibrosis: The Quest for the Right Anticoagulant Continues.

Margaritopoulos GA, Antoniou KM.

Am J Respir Crit Care Med. 2017 Jan 1;195(1):142-143. doi: 10.1164/rccm.201606-1323LE. No abstract available.

PMID:
28035862
16.

Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of FVC percent predicted.

Ward K, Spurr L, Goldman NR, Margaritopoulos GA, Kokosi M, Renzoni E, Chua F, Maher TM, Ward S, Wells AU.

Respir Med. 2016 Nov;120:131-133. doi: 10.1016/j.rmed.2016.10.007. Epub 2016 Oct 14.

17.

Reply.

Margaritopoulos GA, Antoniou KM, Denton CP, Wells AU.

Arthritis Rheumatol. 2017 Jan;69(1):240-241. doi: 10.1002/art.39930. No abstract available.

18.

Toll-like receptors and autophagy in interstitial lung diseases.

Margaritopoulos GA, Lasithiotaki I, Antoniou KM.

Eur J Pharmacol. 2017 Aug 5;808:28-34. doi: 10.1016/j.ejphar.2016.09.032. Epub 2016 Sep 27. Review.

PMID:
27687957
19.

Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy.

Margaritopoulos GA, Vasarmidi E, Antoniou KM.

Core Evid. 2016 Jul 1;11:11-22. doi: 10.2147/CE.S76549. eCollection 2016. Review.

20.

Can Warfarin Be Used in the Treatment of Pulmonary Embolism in Idiopathic Pulmonary Fibrosis?

Margaritopoulos GA, Antoniou KM.

Am J Respir Crit Care Med. 2016 Apr 1;193(7):810-1. doi: 10.1164/rccm.201511-2267LE. No abstract available.

PMID:
27035785
21.

NLRP3 inflammasome expression in idiopathic pulmonary fibrosis and rheumatoid lung.

Lasithiotaki I, Giannarakis I, Tsitoura E, Samara KD, Margaritopoulos GA, Choulaki C, Vasarmidi E, Tzanakis N, Voloudaki A, Sidiropoulos P, Siafakas NM, Antoniou KM.

Eur Respir J. 2016 Mar;47(3):910-8. doi: 10.1183/13993003.00564-2015. Epub 2016 Jan 7.

22.

Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension.

Antoniou KM, Margaritopoulos GA, Goh NS, Karagiannis K, Desai SR, Nicholson AG, Siafakas NM, Coghlan JG, Denton CP, Hansell DM, Wells AU.

Arthritis Rheumatol. 2016 Apr;68(4):1004-12. doi: 10.1002/art.39528.

23.

Smoking and interstitial lung diseases.

Margaritopoulos GA, Vasarmidi E, Jacob J, Wells AU, Antoniou KM.

Eur Respir Rev. 2015 Sep;24(137):428-35. doi: 10.1183/16000617.0050-2015. Review.

24.

Challenges in IPF diagnosis, current management and future perspectives: Patient case 2.

Margaritopoulos G.

Sarcoidosis Vasc Diffuse Lung Dis. 2015 Aug 3;32 Suppl 1:38-9.

PMID:
26237444
25.

Challenges in IPF diagnosis, current management and future perspectives.

Wells AU, Costabel U, Poletti V, Crestani B, Egan J, Margaritopoulos G, Antoniou K.

Sarcoidosis Vasc Diffuse Lung Dis. 2015 Aug 3;32 Suppl 1:28-35. Review.

PMID:
26237442
26.

Smoking-related idiopathic interstitial pneumonia: A review.

Margaritopoulos GA, Harari S, Caminati A, Antoniou KM.

Respirology. 2016 Jan;21(1):57-64. doi: 10.1111/resp.12576. Epub 2015 Jul 2. Review.

27.

Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night.

Schiza S, Mermigkis C, Margaritopoulos GA, Daniil Z, Harari S, Poletti V, Renzoni EA, Torre O, Visca D, Bouloukaki I, Sourvinos G, Antoniou KM.

Eur Respir Rev. 2015 Jun;24(136):327-39. doi: 10.1183/16000617.00009114. Review.

28.

Interstitial lung disease in systemic sclerosis.

Wells AU, Margaritopoulos GA, Antoniou KM, Denton C.

Semin Respir Crit Care Med. 2014 Apr;35(2):213-21. doi: 10.1055/s-0034-1371541. Epub 2014 Mar 25. Review.

PMID:
24668536
29.

Interstitial lung disease.

Antoniou KM, Margaritopoulos GA, Tomassetti S, Bonella F, Costabel U, Poletti V.

Eur Respir Rev. 2014 Mar 1;23(131):40-54. doi: 10.1183/09059180.00009113. Review.

30.

Early diagnosis of IPF: time for a primary-care case-finding initiative?

Antoniou KM, Symvoulakis EK, Margaritopoulos GA, Lionis C, Wells AU.

Lancet Respir Med. 2014 Jan;2(1):e1. doi: 10.1016/S2213-2600(13)70283-2. No abstract available.

PMID:
24461905
31.

Differential telomerase expression in idiopathic pulmonary fibrosis and non-small cell lung cancer.

Antoniou KM, Samara KD, Lasithiotaki I, Margaritopoulos GA, Soufla G, Lambiri I, Giannarakis I, Drositis I, Spandidos DA, Siafakas NM.

Oncol Rep. 2013 Dec;30(6):2617-24. doi: 10.3892/or.2013.2753. Epub 2013 Sep 25.

32.

Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future.

Antoniou KM, Margaritopoulos GA, Siafakas NM.

Eur Respir Rev. 2013 Sep 1;22(129):281-91. doi: 10.1183/09059180.00002113. Review.

33.

Expression of SDF-1/CXCR4 axis in bone marrow mesenchymal stem cells derived from rheumatoid arthritis-usual interstitial pneumonia.

Margaritopoulos GA, Antoniou KM, Lasithiotaki I, Proklou A, Soufla G, Siafakas NM.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4):610-1. Epub 2013 May 27.

PMID:
23710557
34.

Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema.

Tzouvelekis A, Zacharis G, Oikonomou A, Mikroulis D, Margaritopoulos G, Koutsopoulos A, Antoniadis A, Koulelidis A, Steiropoulos P, Boglou P, Bakali M, Froudarakis M, Bouros D.

BMC Pulm Med. 2013 May 22;13:31. doi: 10.1186/1471-2466-13-31.

35.

Self-eating: friend or foe? The emerging role of autophagy in idiopathic pulmonary fibrosis.

Margaritopoulos GA, Tsitoura E, Tzanakis N, Spandidos DA, Siafakas NM, Sourvinos G, Antoniou KM.

Biomed Res Int. 2013;2013:420497. doi: 10.1155/2013/420497. Epub 2013 Apr 10. Review.

36.

An update on idiopathic pulmonary fibrosis.

Margaritopoulos GA, Giannarakis I, Siafakas NM, Antoniou KM.

Panminerva Med. 2013 Jun;55(2):109-20. Review.

PMID:
23676953
37.

Adult Onset Still's Disease: A Case Report with a Rare Clinical Manifestation and Pathophysiological Correlations.

Antoniou KM, Margaritopoulos GA, Giannarakis I, Choulaki C, Fountoulakis N, Siafakas NM, Sidiropoulos P.

Case Rep Med. 2013;2013:981232. doi: 10.1155/2013/981232. Epub 2013 Jan 17.

38.

Warfarin in idiopathic pulmonary fibrosis: friend or foe, is it a matter of genes and heparin?

Tzouvelekis A, Margaritopoulos G, Loukides S, Bouros D.

Am J Respir Crit Care Med. 2013 Jan 15;187(2):213-4. No abstract available.

PMID:
23322796
39.

Sarcoidosis in a 65-year-old woman presenting with a lung mass and pericardial effusion: a case report.

Margaritopoulos GA, Proklou A, Lagoudaki E, Voloudaki A, Siafakas NM, Antoniou KM.

J Med Case Rep. 2012 Aug 31;6:259. doi: 10.1186/1752-1947-6-259.

40.

Investigation of Telomerase/Telomeres system in Bone Marrow Mesenchymal Stem Cells derived from IPF and RA-UIP.

Antoniou KM, Margaritopoulos GA, Proklou A, Karagiannis K, Lasithiotaki I, Soufla G, Kastrinaki MC, Spandidos DA, Papadaki HA, Siafakas NM.

J Inflamm (Lond). 2012 Jul 2;9(1):27. doi: 10.1186/1476-9255-9-27.

41.

Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis.

Margaritopoulos GA, Romagnoli M, Poletti V, Siafakas NM, Wells AU, Antoniou KM.

Eur Respir Rev. 2012 Mar 1;21(123):48-56. doi: 10.1183/09059180.00007611. Review.

42.

Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis.

Samara KD, Antoniou KM, Karagiannis K, Margaritopoulos G, Lasithiotaki I, Koutala E, Siafakas NM.

Int J Oncol. 2012 May;40(5):1397-404. doi: 10.3892/ijo.2012.1374. Epub 2012 Feb 15.

PMID:
22344343
43.

The role of transbronchial biopsy in the diagnosis of diffuse parenchymal lung diseases: con.

Margaritopoulos GA, Wells AU.

Rev Port Pneumol. 2012 Mar-Apr;18(2):61-3. doi: 10.1016/j.rppneu.2011.09.004. Epub 2012 Jan 21. English, Portuguese. No abstract available.

44.

Smoking and pulmonary fibrosis: novel insights.

Samara KD, Margaritopoulos G, Wells AU, Siafakas NM, Antoniou KM.

Pulm Med. 2011;2011:461439. doi: 10.1155/2011/461439. Epub 2011 Jun 15.

45.

Yin Yang-1(YY-1) expression in idiopathic pulmonary fibrosis.

Margaritopoulos GA, Antoniou KM, Soufla G, Vassalou E, Spandidos DA, Siafakas NM.

J Recept Signal Transduct Res. 2011 Apr;31(2):188-91. doi: 10.3109/10799893.2011.557735.

PMID:
21385102
46.

A 35 year old smoker with shortness of breath.

Margaritopoulos GA, Nicholson AG, Giannarakis G, Lambiri I, Siafakas NM, Antoniou KM.

BMJ. 2010 Nov 3;341:c4793. doi: 10.1136/bmj.c4793. No abstract available.

PMID:
21047889
47.

Investigation of angiogenetic axis Angiopoietin-1 and -2/Tie-2 in fibrotic lung diseases: a bronchoalveolar lavage study.

Margaritopoulos GA, Antoniou KM, Karagiannis K, Vassalou E, Lasithiotaki I, Lambiri I, Siafakas NM.

Int J Mol Med. 2010 Dec;26(6):919-23.

PMID:
21042788
48.

Investigation of Toll-like receptors in the pathogenesis of fibrotic and granulomatous disorders: a bronchoalveolar lavage study.

Margaritopoulos GA, Antoniou KM, Karagiannis K, Samara KD, Lasithiotaki I, Vassalou E, Lymbouridou R, Koutala H, Siafakas NM.

Fibrogenesis Tissue Repair. 2010 Oct 11;3:20. doi: 10.1186/1755-1536-3-20.

49.

Expression analysis of Akt and MAPK signaling pathways in lung tissue of patients with idiopathic pulmonary fibrosis (IPF).

Antoniou KM, Margaritopoulos GA, Soufla G, Symvoulakis E, Vassalou E, Lymbouridou R, Samara KD, Kappou D, Spandidos DA, Siafakas NM.

J Recept Signal Transduct Res. 2010 Aug;30(4):262-9. doi: 10.3109/10799893.2010.489227.

PMID:
20536315
50.

Different activity of the biological axis VEGF-Flt-1 (fms-like tyrosine kinase 1) and CXC chemokines between pulmonary sarcoidosis and idiopathic pulmonary fibrosis: a bronchoalveolar lavage study.

Antoniou KM, Soufla G, Proklou A, Margaritopoulos G, Choulaki C, Lymbouridou R, Samara KD, Spandidos DA, Siafakas NM.

Clin Dev Immunol. 2009;2009:537929. doi: 10.1155/2009/537929. Epub 2010 Feb 14.

Supplemental Content

Loading ...
Support Center